These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 12030632)
1. Intravenous immunoglobulins: clinical experience and viral safety. Ballow M J Am Pharm Assoc (Wash); 2002; 42(3):449-58; quiz 458-9. PubMed ID: 12030632 [TBL] [Abstract][Full Text] [Related]
2. Clinical experience with the viral safety of immunoglobulins. Hellstern P Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S31-4; discussion S35. PubMed ID: 7749046 [TBL] [Abstract][Full Text] [Related]
3. Criteria for the appropriate drug utilisation of immunoglobulin. Thürmann P; Harder S Pharmacoeconomics; 1996 May; 9(5):417-29. PubMed ID: 10160254 [TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733 [TBL] [Abstract][Full Text] [Related]
5. The process: New methods of purification and viral safety. Schleis TG Pharmacotherapy; 2005 Nov; 25(11 Pt 2):73S-77S. PubMed ID: 16229677 [TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Hooper JA Immunol Allergy Clin North Am; 2008 Nov; 28(4):765-78, viii. PubMed ID: 18940573 [TBL] [Abstract][Full Text] [Related]
8. Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Dodd RY Clin Exp Immunol; 1996 May; 104 Suppl 1():31-4. PubMed ID: 8625541 [TBL] [Abstract][Full Text] [Related]
9. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Troccoli NM; McIver J; Losikoff A; Poiley J Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036 [TBL] [Abstract][Full Text] [Related]
10. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates. Burnouf T Biologicals; 1992 Jun; 20(2):91-100. PubMed ID: 1389114 [TBL] [Abstract][Full Text] [Related]
11. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates. Goldsmith JC Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015 [TBL] [Abstract][Full Text] [Related]
12. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Kempf C; Stucki M; Boschetti N Biologicals; 2007 Mar; 35(1):35-42. PubMed ID: 16581263 [TBL] [Abstract][Full Text] [Related]
15. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization. Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665 [TBL] [Abstract][Full Text] [Related]
16. [Immunoglobulin preparations]. Ono Y Nihon Rinsho; 2012 Apr; 70(4):629-34. PubMed ID: 22568145 [TBL] [Abstract][Full Text] [Related]
17. [High dose intravenous immunoglobulins in therapeutic arsenal in autoimmune and systemic diseases]. Klein M; Kaminsky P; Duc M Therapie; 1993; 48(2):97-103. PubMed ID: 8351694 [TBL] [Abstract][Full Text] [Related]
18. Requirements for safety and quality of intravenous immunoglobulin G preparations. Rütter GH J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):2-5. PubMed ID: 7964845 [TBL] [Abstract][Full Text] [Related]
19. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Lebing W; Remington KM; Schreiner C; Paul HI Vox Sang; 2003 Apr; 84(3):193-201. PubMed ID: 12670368 [TBL] [Abstract][Full Text] [Related]